I think at this stage, one can conclusively say, Her-Vaxx wins hands down in the toxicity and tolerability departments. There can be no dispute there. And that is half the war won.
As far as efficacy is concerned, it is still a bit up in the air. But so far, it is comparable to Herceptin although that needs to be confirmed by further results.
Ann: Imugene HER-Vaxx Phase 2 PFS Data and Flags Three New Trials, page-181
-
- There are more pages in this discussion • 165 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $356.9M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 4.9¢ | 4.8¢ | $328.5K | 6.792M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 45 | 5443565 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 2171910 | 5 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |